The partnership between Europe and developing countries for clinical trials (EDCTP) is providing funding of 10 million euros over five years for the “WANECAM 2” project. This grant will support clinical trials in Africa on a new antimalarial combination, KAF156 (ganaplacide) and lumefantrine, taken as a single daily dose. The KAF156 compound has been shown to have the potential to treat resistant malaria and could be administered in a single-dose form. The grant will also help build and strengthen research capacities in the four participating countries: Burkina Faso, Gabon, Mali, and Niger.
